Patient Guide - Important information on minimising the risk of adverse events

Prescriber’s Guide - Important information on minimising the risk of adverse events

Mayzent UK RMP Patient and Caregiver Guide

Mayzent UK RMP Prescribers Checklist

Methotrexate Patient Alert Card

HCP guide on minimising the risks of cardiac adverse events and severity of adverse reactions in those with hepatic impairment

Mexiletine hydrochloride 50 mg, 100 mg, 200 mg Hard Capsules contain mexiletine and some patients taking mexiletine may develop cardiac arrhythmia which can be life-threatening. This Patient alert card provides important information to patients about their treatment and aims to raise awareness and inform healthcare providers and pharmacists about the ongoing medication the patient is taking and the risk of cardiac arrhythmia which can be life-threatening.

HCP guide on minimising the risks of cardiac adverse events and severity of adverse reactions in those with hepatic impairment and blood dyscrasias.

Mexiletine hydrochloride 100 mg and 200 mg hard capsules contain mexiletine and some patients taking mexiletine may develop irregular heart beats which can be life-threatening. This Patient alert card provides important information to patients about their treatment and aims to raise awareness and inform healthcare providers and pharmacists about the ongoing medication the patient is taking and the risk of cardiac arrhythmia which can be life-threatening.

MULTAQ® (dronedarone) PRESCRIBER GUIDE

This guide contains important safety information for the safe use of dronedarone.

For hard copies please contact our medical information department at 0800 035 2525 or email [email protected]

Healthcare professional guide contains information on the specific risks associated with Myalepta and the measures designed to address them along with the potentially serious adverse drug reactions.

This document contains important risk minimisation information for patients and their carers.

Provides patients and their carers important information on how to reconstitute and administer Myalepta (metreleptin).

This document contains important risk minimisation information for patients and their carers.

Mycophenolate mofetil Guide for Healthcare Professionals

Mycophenolate mofetil Guide for Patients

RMM Mynzepli UK HCP Admin Guide

RMM MYNZEPLI UK patient guide – AMD

RMM MYNZEPLI UK patient guide - DME

RMM MYNZEPLI UK patient guide - mCNV

RMM MYNZEPLI UK patient guide - RVO

IMPORTANT INFORMATION for healthcare professionals on risks associated with alglucosidase alfa administration, clinical management of infusion-associated reactions, immune-mediated reactions and immunology testing

This Information Guide is intended for healthcare professionals involved in the prescribing and dispensing of thalidomide and contains information about the Thalidomide Pregnancy Prevention Programme including risk minimisation measures before prescribing or dispensing thalidomide in order to avoid harm to unborn babies, and other side effects of thalidomide.

This Information Guide for patients contains information about the Thalidomide Pregnancy Prevention Programme including risk minimisation measures to avoid harm to unborn babies and how to report side effects.

Thalidomide 100mg Adverse Event Form.

This Risk Awareness Form is to assist healthcare professionals with counselling a patient before they commence thalidomide treatment to ensure patient is fully aware of the risks and the safe use of thalidomide. It must be completed for each male patient before the start of treatment.

This card should be given to the patient as a reminder of the most important information and risks of treatment with thalidomide.

Thalidomide 100mg Pregnancy Outcome Form

Thalidomide 100mg Pregnancy Report Form

This Risk Awareness Form is to assist healthcare professionals with counselling a patient before they commence thalidomide treatment to ensure the patient is fully aware of the risks and the safe use of thalidomide. It must be completed for each female patient of childbearing potential before the start of treatment.

This Risk Awareness Form is to assist healthcare professionals with counselling a patient before they commence thalidomide treatment to ensure the patient is fully aware of the risks and the safe use of thalidomide. It must be completed for each female patient of non-childbearing potential before the start of treatment.

The Physician Prescribing Checklist (PPC) for Mysimba® is designed to support appropriate prescribing and ensure safe use of the product among UK healthcare professionals.

Following a previous PASS (Study NB-452) that assessed the effectiveness of the PPC in improving physician knowledge and understanding, a follow-up qualitative study (NB-453) using online focus groups was conducted to explore physician attitudes, understanding, and behaviour related to PPC use.

This follow-up was initiated after some assessment thresholds were not fully met in the initial study. The final results of Study NB-453, along with the updated Risk Management Plan (RMP v.12.10), have been approved to support ongoing risk minimisation efforts.